President Trump's executive order to separate the combined MMR vaccine into individual shots faces significant regulatory and manufacturing challenges, with FDA approval potentially taking up to 10 years. Merck and GSK, the only licensed producers of the combined MMR vaccine, have not manufactured individual vaccines for decades and cite lack of scientific support for the split. Meanwhile, IBM is enhancing its AI capabilities by integrating OpenAI models like GPT-5.6 into its consulting platform, aiming to advance enterprise AI and cybersecurity solutions. Jack in the Box is showing early signs of operational improvement under interim leadership but continues to face challenges in a tough quick-service restaurant market. Additionally, investor Michael Burry is increasing short positions on several tech stocks, citing overvaluations after recent rallies.
The Invesco S&P 500 Momentum ETF (SPMO) underwent a semi-annual reconstitution, resulting in 54 changes affecting about 40% of its portfolio. Apple and Merck were the largest additions, while Nvidia was removed despite a strong one-year gain of over ...
Moderna's shares surged 9% after its Phase 3 melanoma study was selected for a prestigious Presidential Symposium slot at the European Society for Medical Oncology congress. This high-profile placement signals strong confidence in the study's potenti...
Amgen and Merck both pay quarterly dividends and raise them annually, but Amgen offers a higher yield (2.6% vs. 2.29%) and has consistently raised dividends by about 6% annually. While Merck relies heavily on its Keytruda franchise, facing a looming ...
Pfizer has paused its annual dividend increase for the first time in over a decade, maintaining a quarterly payout of $0.43 throughout 2026. This pause comes despite a strong 6.2% dividend yield and solid adjusted earnings coverage, reflecting cautio...
Moderna's stock surged 6% to $154, extending a 137% gain over the past month driven by promising Phase 2b melanoma vaccine data presented at ASCO 2026. The data showed a 49% reduction in risk of recurrence or death when combining Moderna's intismeran...
